李秀艳博士，现任年衍药业CTO， 负责公司的早期研发，CMC，质量及供应链的运营。曾联合创立美国汇智协和（PharmaSynergy），中国药企国际化及跨境合作的战略伙伴。1981至1989年于北京大学化学系学习，1995年获美国康州大学药学博士。曾任职J&J， AMRI, Covidien,方达，药明康德等多家国内国外知名企业。她从一线研发科学家成长为跨界产品创新的领军人，直接领导并参与了多个新药，仿制药，大健康产品， 原料药，辅料，高纯试剂及材料的开发，包括生产工艺开发，分析方法开发，中试生产，及大规模生产的技术转移。在美国强生期间负责产品的全球外包生产和新剂型产品的创新合作，任McNeil OTC业务创新委员会核心成员。外包产品价值2.5亿美元，合作开发产品管线价值10亿美元。参与或领导的项目包括复杂缓控释制剂，透皮给药贴片，软胶囊复杂复方制剂，儿童剂型包括口服液，口崩片，颗粒剂，掩味技术，儿童洗浴护肤品，益生菌保健产品等。得益于与超过200多家的CRDMO，DDS，Biotech and pharma企业的交流访问及合作，积累了丰富的技术评估，外包和供应商尽职调查，合同洽谈的经验。回国后任职药明康德，领导在中国的大健康产品开发和申报的服务，向中国引进先进的健康产品和技术，帮助中国企业国际化。2016年合伙创立汇智协和，业务的重点是帮助中国企业在新形势下以合作多赢的方式尽快建立长期战略合作部局，以领先进入中国市场的特色仿制药及适合中国市场的505b2创新仿制药和创新药为重点，参与了涉及中美欧日台印多方合作的多个JV公司的筹划，尽职调查，合同洽谈。同时帮助华人新药技术公司及国内药企与国外企业开展多层次合作。现兼任世中联经皮给药专业委员会副会长负责国际合作。现为6D孵化的聚焦肾病创新的年衍药业核心成员。

Dr. Cheryl Li, currently CTO of Nicoya Therapeutics, formerly CEO and CO-founder of PharmaSynergy, was honored to have served in several reputable CRDMOs, global pharmaceutical companies including Wuxi Apptec, J&J, Covidien, AMRI. She has over 25 years in-depth industry experience with increasing responsibilities in a wide range of professional areas including drug discovery and CMC product development (API and FGs), R&D outsourcing, external manufacturing, product in-licensing and strategic partnership, product due diligence, and business contract negotiations. She had the opportunity to visit and work with more than 200 CRO/CMO and DDS firms globally and is familiar with how the

businesses are conducted in different parts of the world.

She received her Ph.D. degree in Pharmaceutical Sciences from UCONN, MS and BS degrees in Chemistry from Peking University. She has been widely involved in various professional organizations, currently serving as VP of China Transdermal Society. She is a

Member of SAPA, ACS and AAPS.